Lung transplantation (LTx) faces a suboptimal organ allocation scheme, with long waiting times and high waiting list mortality for transplant candidates. Although the lung allocation score (LAS) stratifies recipient risk and contributes to lowering waiting time, mortality remains 15% for adult and 22% for pediatric patients awaiting LTx. On the other hand, only 20% of all multiorgan donors are utilized for LTx in the United States, compared with 50% in European countries. An important factor contributing to the apparent shortage of organs in the United States is the usage of nonstandardized and often stringent donor selection criteria: Over 15 different characteristics and their combined effect is largely unknown. Other solid organ transplant groups have successfully devised comprehensive donor risk stratification systems based on the combined impact of these characteristics to standardize their matching process. For example, the kidney donor profile index, adapted by the United Network for Organ Sharing (UNOS) in 2014, resulted in increased utilization of organs, and the interpretation of data. All authors wrote the article and were involved in critical review.

Supplemental digital content (SDC) is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal’s Web site (www.transplantjournal.com). Correspondence: Farhan Zafar, MD, Cincinnati Children’s Hospital Medical Center. 3333 Burnet Ave, Cincinnati, OH 45229. (farhan.zafar@cchmc.org). Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

ISSN: 0041-1337/20/10610-2019
DOI: 10.1097/TP.0000000000004131
increased transplant rates for the most difficult-to-match patients, reaching up to 6-fold in some cases, with better or at least similar early graft survival.6–9 There is a need for a similar tool to quantify the risk for LTx and allow better and more standardized recipient-donor matching.

There is increasing evidence from the LTx community, and from other solid organ transplantation, that high-risk donors can be matched to certain recipients without compromising outcomes while increasing organ utilization rate. However, this does not hold true for all cohorts of recipients.10–16 An allocation system based on recipient, donor, and transplant characteristics rather than just recipient characteristics may optimize both clinical outcomes and organ utilization nonetheless. A recently introduced mortality after lung transplantation score does incorporate both donor and recipient factors and improves upon other risk scores but is limited by use of short-term survival.17

Our aim is to take initial steps to developing a LTx allocation system that focuses on increasing utilization but also the number of years alive with a transplant for the whole community maximize benefit from a limited donor pool. We took advantage of new statistical methodologies and the incorporation of machine and deep learning into prediction models to develop an objective risk scoring model that includes recipient, donor, and transplant factors. For demonstrating an wider applicability of the proposed risk scoring model, a web-based clinical tool that can predict the median survival time and the 1-, 5-, and 10-y survival probabilities of possible recipient-donor matches was also developed.

MATERIALS AND METHODS

All UNOS patients who received a double LTx between January 2005 and March 2020 and were aged ≥12 y at transplant were eligible for analysis. This age cutoff was used because a similar allocation system and LAS are applicable to candidates ≥12 y. Patients who received retransplantations, those who had other solid organ transplant simultaneously or had missing posttransplant survival status were excluded. Details of how the recipient, donor, and transplant variables were selected, and the methods to assign a risk score are provided in the Supplement (SDC, http://links.lww.com/TP/C396).

The categories for the variables were formed using prior published work (age and estimated glomerular filtration rate [eGFR]) and clinical relevant cutoffs (Karnofsky Performance Status and eGFR). Missing data were imputed for records with only a single missing data point, whereas records with multiple missing data points were excluded. Imputation of missing data for recipient and donor variables was conducted separately using the recipient-donor match to the cluster with the largest probability.

We calculated model-based short-, medium-, and long-term survival probabilities and their 95% confidence interval (CI) for each risk group in the validation cohort data and compared them with the observed percentages. We also compared the derivation and validation cohorts by examining the Kaplan-Meier (KM) survival curves of each risk group and by computing the hazard ratios between risk groups. All statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC) and R version 3.5.0 (R Core Team, 2018). The glmnet (V2. 0-18), an R package was used to perform the variable selection analyses. Institutional Review Board was obtained, and patient consent was waived.

According to algorithms discussed above, a web-based tool was designed to make predictions on long-term (1, 5, and 10 y) survival probabilities and half-life for any given recipient-donor match. The goal was to provide a tool to make an informed decision for the recipients at the time of transplant.

RESULTS

A total of 19,263 eligible double LTxs were performed in the study period, and 15,124 were included in the analysis. Cohort selection is detailed in Figure 1. Details on missing data and imputation results are presented in the Supplement (SDC, http://links.lww.com/TP/C396).

The study cohort was randomly subdivided into a derivation cohort of 10,660 (70%) cases and a validation cohort of 4,464 (30%). Continuous recipient, donor, and transplant data for the derivation and validation cohorts were summarized as median with interquartile range (IQR) and discrete data as percentage with frequency. Nonparametric tests (Mann-Whitney U test) were used for testing the difference between 2 medians, and χ² test for testing differences between 2 proportions. The comparison between derivation and validation cohorts for each of the recipient, donor, and transplant characteristics is presented in Table 1.

All recipient, donor, and transplant variables with categorical levels reported in Table 1 are included in 3 competing models: Cox-Lasso regression model, Cox regression with backward elimination, and random forest Cox. The optimal lambda (0.011) in Cox-Lasso was within the range of minimum mean crossvalidated error and 1 SE of the minimum and assigned to a value to ensure a balance between model over-fitting and simplicity. We observed less predictive ability with the validation cohort of the other 2 methods, Cox regression with backward elimination and random forest Cox, compared with Cox-Lasso. Specifically, we observed that the 95% CI for the survival probability for the medium- and high-risk groups was overlapping using the other 2 methods. In Table S1 (SDC, http://links.lww.com/TP/C396), we provide the list of variables selected by each of these methods. Overall, the Cox-Lasso provided a more clinically interpretable list of
variables. The variables included in the model were divided into recipient-, donor-, and transplant-specific variables. The recipient variables were age, race, body mass index, initial and end LAS, diagnosis, Karnofsky Performance Status, eGFR, albumin, tobacco, steroid, extracorporeal mechanical oxygenation (ECMO), and ventilator. The donor variables were age, race, tobacco, and diabetes, and the transplant-related variables included cytomegalovirus mismatch and ischemia time (6 h). The regression coefficient estimates of all these variables with 95% CIs are reported in Table 2.

Model Validation

Given the covariate levels of each recipient, the adjusted total risk score was computed for every recipient and Figure 2A shows its density plot. The median of the adjusted total score was 42 (IQR, 31–55). The median survival time with 95% CI for each adjusted total risk score using the Cox regression model is plotted in Figure 2B. We also examined the model’s prediction ability by using the adjusted total risk score for short-, medium-, and long-term survival. The C statistics for the mortality of 1, 5, and 10 y were 0.67, 0.64, and 0.72, respectively. These values were acquired from logistic regression models wherein binary indicators were used for 1-, 5-, and 10-y mortality as outcomes and adjusted total risk score as the only covariate.

The adjusted total scores were grouped into 3 clusters by using the expectation-maximization algorithm (Figure 3). The median (IQR) of the adjusted total score was 15 (10–19) in the low-risk cluster, 39 (33–44) in the medium-risk cluster, and 61 (56–68) in the high-risk cluster. The distribution of cases by risk group was very similar for derivation and validation cohorts (Table 3). The observed survival rates by risk group in the validation cohort were within the model estimated 95% CIs, indicating that the model fit was good. The only exception was for 1-y survival in the high-risk group. For each risk group, the KM survival curves from the derivation cohort with 95% CIs (solid line with shaded area in Figure 4) and from the validation cohort (dotted line with shaded area in Figure 4) indicated that good validation criteria were met. The P values from the log rank tests for the similarity of 2 KM curves in low-, medium-, and high-risk groups are 0.42, 0.98, and 0.78, respectively. Again, the similarities in hazard ratio estimates between derivation and validation cohorts (Table 3 and Figure 5A and B) provide evidence in support of the Cox-Lasso model.

To make this Lung Transplantation Advanced Prediction Tool (LAPT) readily available for clinicians, a webpage was developed in Hypertext Markup Language with LAPT presented in the form of a simple calculator (link: https://lungscore.research.cchmc.org/96b53228-4cbf-0bbf-59bf7733d7056). Users can enter recipient, donor, and transplant information to learn the predicted 1-, 5-, 10-y survival, risk classification and associated survival and half-life prediction, an example highlighted in Figures 6 and 7.

DISCUSSION

Presently, the lung allocation system is recipient centric depending mainly on the LAS score, which is derived from recipient characteristics. Matches are made based on LAS and on individual programs’ perception of how different donor and transplant characteristics may or may not affect their patient’s outcome. However, a complimentary tool developed using machine learning algorithms (MLAs)
## TABLE 1.
Comparison of recipient, donor, and transplant characteristics by derivation and validation cohorts using the recipient, donor, and transplant characteristics available in UNOS national data set

| Characteristic type/measures | Validation | Derivation | p² |
|-----------------------------|------------|------------|----|
| **Recipient characteristics** |            |            |    |
| Age median, y               | 57 [46–63] | 57 [45–63] | 0.5284 |
| Age groups                  |            |            | 0.0509 |
| 12–29                       | 10.7% (478) | 11.4% (1215) |    |
| 30–49                       | 19.6% (876) | 19.8% (2112) |    |
| 50–59                       | 30.1% (1343) | 27.7% (2953) |    |
| 60–64                       | 20.0% (893) | 20.7% (2209) |    |
| ≥65                         | 19.6% (874) | 20.4% (2171) |    |
| Sex                         |            |            | 0.1377 |
| Female                      | 41.4% (1847) | 42.7% (4550) |    |
| Male                        | 58.6% (2617) | 57.3% (6110) |    |
| Race/ethnicity              |            |            | 0.9404 |
| White                       | 79.7% (3557) | 79.5% (8470) |    |
| Black                       | 10.3% (462) | 10.4% (1106) |    |
| Hispanic                    | 7.3% (327) | 7.6% (810) |    |
| Other                       | 2.6% (118) | 2.6% (274) |    |
| Body mass index, kg/m²      | 25.3 [21.2–28.7] | 25.0 [21.1–28.6] | 0.0624 |
| Diagnosis                   |            |            | 0.3287 |
| Obstructive lung disease    | 28.2% (1259) | 28.5% (3034) |    |
| Pulmonary vascular disease  | 4.9% (217) | 5.1% (544) |    |
| Cystic fibrosis             | 16.3% (729) | 17.3% (1842) |    |
| Restrictive lung disease    | 50.6% (2259) | 49.2% (5240) |    |
| Initial LAS                 | 37.3 [33.6–44.8] | 37.1 [33.6–44.5] | 0.8107 |
| End LAS                     | 41.6 [35.3–55.2] | 41.1 [35.3–55.5] | 0.8387 |
| Functional status (KPS)     |            |            | 0.6286 |
| <30                         | 15.2% (678) | 14.9% (1592) |    |
| 30–59                       | 42.4% (1893) | 43.3% (4611) |    |
| ≥60                         | 42.4% (1893) | 41.8% (4457) |    |
| eGFR, mL/min/1.73 m²        | 101 [81–126] | 101 [80–126] | 0.6204 |
| Albumin, g/dL               | 3.90 [3.50–4.30] | 3.90 [3.50–4.30] | 0.2174 |
| Tobacco use                 |            |            | 0.3375 |
| No                          | 45.2% (2016) | 46.0% (4905) |    |
| Yes                         | 54.8% (2448) | 54.0% (5755) |    |
| Recent infection            |            |            | 0.5090 |
| No                          | 86.0% (3840) | 85.6% (9126) |    |
| Yes                         | 14.0% (624) | 14.4% (1534) |    |
| Steroid use                 |            |            | 0.3542 |
| No                          | 55.3% (2468) | 56.1% (5981) |    |
| Yes                         | 44.7% (1996) | 43.9% (4679) |    |
| ECMO pretransplant          |            |            | 0.4078 |
| No                          | 94.6% (4222) | 94.9% (10 117) |    |
| Yes                         | 5.4% (242) | 5.1% (543) |    |
| Ventilation pretransplant   |            |            | 0.4287 |
| No                          | 93.6% (4179) | 93.3% (9942) |    |
| Yes                         | 6.4% (285) | 6.7% (718) |    |
| CMV                         |            |            | 0.5739 |
| Negative                    | 45.9% (2047) | 45.4% (4835) |    |
| Positive                    | 54.1% (2417) | 54.6% (5825) |    |
| **Donor characteristics**   |            |            |    |
| Age median, y               | 32 [22–46] | 32 [22–46] | 0.6643 |
| Age groups                  |            |            | 0.6811 |
| <50                         | 80.7% (3604) | 81.0% (8637) |    |
| ≥50                         | 19.3% (860) | 19.0% (2023) |    |
| Sex                         |            |            | 0.4475 |
| Female                      | 40.1% (1789) | 40.7% (4343) |    |
| Male                        | 59.9% (2675) | 59.3% (6317) |    |
| Race/ethnicity              |            |            | 0.0266 |
| Other                       | 82.5% (3685) | 81.0% (8636) |    |
| Black                       | 17.5% (779) | 19.0% (2024) |    |

*Continued next page*
that matches recipient and donor, based on their respective risk factors, and includes transplant-related factors to optimize the best pairing is not far-reaching. In fact, the use of machine learning compared with other methods, is more effective and efficient at detecting hidden patterns in large data sets. MLAs are being used in other solid organ transplants. A new allocation system for kidney transplant was proposed, with different combination of variables

### TABLE 1. (Continued)

| Characteristic type/measures | Validation | Derivation | \(P^\) |
|------------------------------|------------|------------|---------|
| Body mass index, kg/m\(^2\) | 25.2 [22.3–29.0] | 25.3 [22.4–29.0] | 0.7808 |
| Tobacco use | | | 0.7566 |
| No | 92.0% (4106) | 92.1% (9821) | 0.5446 |
| Yes | 8.0% (358) | 7.9% (893) | |
| Hypertension | | | 0.2819 |
| No | 76.8% (3430) | 76.4% (8142) | 0.5901 |
| Yes | 23.2% (1034) | 23.6% (2518) | |
| Diabetes | | | 0.7476 |
| No | 93.1% (4155) | 92.6% (9869) | 0.2028 |
| Yes | 6.9% (309) | 7.4% (791) | |
| Bronchoscopy abnormal | | | 0.4060 |
| No | 73.0% (3257) | 73.4% (7823) | 0.5901 |
| Yes | 27.0% (1207) | 26.6% (2837) | |
| Chest X-ray abnormal | | | 0.2028 |
| No | 41.1% (1834) | 42.2% (4499) | 0.4060 |
| Yes | 58.9% (2630) | 57.8% (6161) | |
| HIV | | | 0.7476 |
| No | 82.4% (3680) | 82.7% (8811) | 0.2028 |
| Yes | 17.6% (784) | 17.3% (1849) | |
| Recent infection | | | 0.6463 |
| No | 31.1% (1388) | 31.5% (3355) | 0.3321 |
| Yes | 68.9% (3076) | 68.5% (7305) | |
| Pa\(_o\)/Fi\(_O\(_2\)\) \(<200\) | 1.4% (64) | 1.4% (150) | |
| 200–299 | 6.7% (301) | 6.7% (713) | |
| 300–399 | 25.6% (1143) | 26.9% (2872) | |
| \(\geq400\) | 66.2% (2956) | 65.0% (6925) | |
| PEEP | | | 0.4060 |
| \(\leq5\) | 81.1% (3620) | 81.8% (8716) | 0.7469 |
| >5 | 18.9% (844) | 18.2% (1944) | |
| Adjusted tidal volume | | | 0.6463 |
| \(\leq8\) | 26.9% (1199) | 27.0% (2875) | 0.4060 |
| 8–12 | 65.5% (2922) | 65.7% (7004) | 0.2028 |
| >12 | 7.7% (343) | 7.3% (781) | |
| Arterial blood pH | 7.42 [7.38–7.46] | 7.42 [7.38–7.46] | |
| Arterial blood \(-\text{HCO}_3\) | 23.8 [21.5–26.2] | 23.7 [21.2–26.3] | |
| Deceased donor cause of death | | | 0.9791 |
| Other | 67.8% (3025) | 67.8% (7226) | 0.3321 |
| Cerebrovascular/stroke | 32.2% (1439) | 32.2% (3434) | 0.4060 |
| Circumstance of death | | | 0.6812 |
| Other | 82.7% (3690) | 82.4% (8782) | 0.6812 |
| MVA | 17.3% (774) | 17.6% (1878) | |
| Mechanism of death | | | 0.5583 |
| Other | 67.3% (3006) | 66.8% (7126) | 0.5583 |
| Intracranial hemorrhage/stroke | 32.7% (1458) | 33.2% (3534) | 0.6287 |
| CMV | | | 0.6287 |
| Negative | 37.6% (1679) | 37.2% (3965) | 0.0476 |
| Positive | 62.4% (2785) | 62.8% (6695) | 0.0476 |
| Transplantation characteristics | | | 0.7511 |
| Ischemic time median, h | 5.48 [4.55, 6.52] | 5.48 [4.53, 6.52] | 0.7511 |
| Ischemic time groups | | | 0.9940 |
| \(<6\) h | 63.3% (2824) | 63.3% (6743) | 0.9940 |
| \(\geq6\) h | 36.7% (1640) | 36.7% (3917) | 0.9940 |

\(^{\text{a}}\)Continuous data were compared using Wilcoxon rank-sum test and were reported as median [interquartile range]. Categorical variables were compared using \(\chi^2\) analysis and are reported as % (n). CMV, cytomegalovirus; ECMO, extracorporeal mechanical oxygenation; eGFR, estimated glomerular filtration rate; KPS, Karnofsky Performance Status; LAS, lung allocation score; MVA, motor vehicle accident; PEEP, positive end-expiratory pressure; UNOS, United Network for Organ Sharing.
### TABLE 2.
Estimation of regression coefficients with 95% CIs from the Cox-Lasso regression using derivation cohort

| Variable names | Labels | Coefficients | 95% CI          |
|----------------|--------|--------------|-----------------|
| **Recipient variables** |        |              | Lower    | Upper    |
| Age, y         | 12–30  | 0            |           |          |
|                | 30–50  | −0.2817      | −0.3537   | −0.2275  |
|                | 50–60  | −0.1037      | −0.1764   | −0.0773  |
|                | 60–65  | 0            |           |          |
|                | ≥65    | 0.1811       | 0.1798    | 0.3008   |
| Race           | White  | 0            |           |          |
|                | Black  | 0.0150       | 0.0093    | 0.1913   |
|                | Hispanic | 0            |           |          |
|                | Other  | 0            |           |          |
| BMI, kg/m²     | <18.5  | 0            |           |          |
|                | 18.5–30| −0.0874      | −0.2185   | −0.0526  |
|                | ≥30    | 0            |           |          |
| Diagnosis groups |        |              |           |          |
| Obstructive pulmonary disease | 0 | | |
| Pulmonary vascular disease | 0.0108 | 0.0178 | 0.2821 |
| Cystic fibrosis | −0.0254 | −0.1921 | −0.0044 |
| Restrictive pulmonary disease | 0 | | |
| LAS            | <50    | 0            |           |          |
|                | 50–75  | 0.0348       | −0.0074   | 0.1781   |
|                | ≥75    | 0            |           |          |
| End LAS        | <50    | 0            |           |          |
|                | 50–75  | 0            |           |          |
|                | ≥75    | 0.0179       | −0.0487   | 0.1341   |
| KPS            | <30    | 0            |           |          |
|                | 30–60  | 0            |           |          |
|                | ≥60    | −0.0654      | −0.2152   | −0.0408  |
| eGFR, mL/min   | <50    | 0            |           |          |
|                | <50    | 0.1726       | 0.1092    | 0.4406   |
| Albumin, g/dL  | <3.4   | 0            |           |          |
|                | ≥3.4   | −0.0350      | −0.1921   | −0.0143  |
| Tobacco use    | Yes    | 0.0305       | 0.0197    | 0.1552   |
| Steroid        | Yes    | 0.0105       | 0.0029    | 0.1036   |
| ECMO pretransplant | Yes | 0.0148 | −0.0358 | 0.2377 |
| Ventilator pretransplant | Yes | 0.0660 | −0.0311 | 0.2106 |
| **Donor variables** |        |              |           |          |
| Age, y         | <50    | 0            |           |          |
|                | ≥50    | 0.0778       | 0.0261    | 0.1837   |
| Race           | Other  | 0            |           |          |
|                | Black  | 0.0378       | 0.0229    | 0.1746   |
| Tobacco use    | Yes    | 0.0289       | 0.0166    | 0.2057   |
| Steroid        | Yes    | 0.0105       | 0.0029    | 0.1036   |
| Diabetes       | Yes    | 0.0053       | 0.0018    | 0.1958   |
|                | No     | 0            |           |          |
| **TX variables** |        |              |           |          |
| CMV mismatch   | Yes    | 0.0316       | 0.0270    | 0.1356   |
|                | No     | 0            |           |          |
| Ischemia time  | <6     | 0            |           |          |
|                | ≥6     | 0.0506       | 0.0303    | 0.1444   |

BMI, body mass index; CI, confidence interval; CMV, cytomegalovirus; ECMO, extracorporeal mechanical oxygenation; eGFR, estimated glomerular filtration rate; KPS, Karnofsky Performance Status; LAS, lung allocation score; TX, transplantation.
used for 2 separate age groupings based on coefficients from an ensemble of statistical methods, including the Lasso models.21 MLAs were also used in the liver transplantation field in an Australian study predicting early graft rejection.22 Another study reported that the compilation of liver recipient and donor factors provided better 3-mo prediction of graft survival compared with using isolated donor and recipient factors for matching.23

In the LTx field, MLAs are still not widely utilized, and LAS continues to be the main factor used to determine transplant urgency. Nevertheless, majority of patients listed for LTx fall under a narrow range of LAS values, with only 17% having a score greater than 50 in 2018.24 Therefore, using LAS alone does not account for the heterogeneity of recipients. Furthermore, donor factors should be accounted for, and some clinicians have proposed matching based on donor and recipient factors, employing beyond the usual donor factors of ABO and height compatibility. Evidence supporting matching on age has been reported that corroborate our finding of age as a major influence on both donor and recipient scores.25,26 Subsequently, Hall et al concluded that although donor-to-recipient age matching was not an independent risk factor, it should still be included when considering the totality of

FIGURE 2. Adjusted total scores from Cox-Lasso model using the derivation cohort. A, Distribution of adjusted total score. B, Median survival time with 95% confidence interval (CI) for each adjusted total risk score using the Cox regression model.

FIGURE 3. The grouping of adjusted total scores in 3 clusters from expectation-maximization (EM) clustering algorithm.
TABLE 3.
Validation results for checking the adequacy of Cox-Lasso model derived from the derivation cohort when applied to validation cohort

| Optimal model results | Low risk | Medium risk | High risk |
|-----------------------|----------|-------------|-----------|
| No. of recipients     |          |             |           |
| Derivation, n (%)     | 1581 (14.8%) | 5799 (54.4%) | 3280 (30.8%) |
| Validation, n (%)     | 664 (14.9%) | 2465 (55.2%) | 1335 (29.9%) |
| Total, n (%)          | 2245 (14.8%) | 8264 (54.6%) | 4615 (30.5%) |
| Mortality rates (validation cohort) |          |             |           |
| 1 y                   |          |             |           |
| Model estimated       | 91.4% (90.0%–92.7%) | 87.9% (86.8%–89.0%) | 83.7% (82.1%–85.3%) |
| Observed              | 91.4%    | 89.0%       | 81.6%     |
| 5 y                   |          |             |           |
| Model estimated       | 71.3% (67.8%–75.0%) | 61.6% (59.5%–63.8%) | 51.3% (48.3%–54.5%) |
| Observed              | 70.6%    | 61.3%       | 52.6%     |
| 10 y                  |          |             |           |
| Model estimated       | 51.9% (46.9%–57.3%) | 39.1% (36.0%–42.4%) | 27.4% (24.0%–31.4%) |
| Observed              | 54.7%    | 38.3%       | 27.6%     |
| Hazard ratio: (95% CI); P |          |             |           |
| Derivation Reference  | 1.55 (1.39-1.72); P < 0.0001 | 2.12 (1.90-2.37); P < 0.0001 |
| Validation Reference  | 1.43 (1.22-1.68); P < 0.0001 | 1.97 (1.67-2.33); P < 0.0001 |

CI, confidence interval.

donor and recipient characteristics. This suggests that organs should not be refused based on advanced donor age alone. These studies support our purpose of looking at the interplay of all factors for every patient.

FIGURE 4. Kaplan-Meier (KM) curves from derivation cohort (solid line with 95% confidence intervals [CIs] in shaded area) and from validation cohort (dotted line) for high-, medium-, and low-risk groups.
Other risk factors have also been considered like cytomegalovirus mismatch and ECMO use. Previous studies have suggested that donor and recipient cytomegalovirus mismatch increases the risk of mortality in LTx patients.28,29 Similar results were reported in our model in which cytomegalovirus mismatch was found to be a significant risk factor. Similar pattern was also seen when considering ECMO use. In fact, prolonged waitlist times have prompted more ECMO use as a bridge to LTx, and ECMO was found to be a significant risk factor that affects posttransplantation survival. Therefore, including ECMO use into the risk score prediction is essential.

**FIGURE 5.** Survival probability comparisons among risk groups. A, Hazard ratio estimates with pairwise risk group comparisons for derivation cohort, and the survival probability with 95% confidence intervals (CIs) for each risk group. B, Hazard ratio estimates with pairwise risk group comparisons for validation cohorts and the survival probability with 95% CIs for each risk group.

**FIGURE 6.** Web application example (screenshot) Example 1: A 55-y-old Black female patient diagnosed with obstructive lung disease (COPD) with low estimated glomerular filtration rate (eGFR; <50 mL/min) receiving lungs from a Black donor aged <50 y, nonsmoker, and does not have diabetes. Transplant had a good ischemia time (<6 h). The patient has a 59.6% chance of falling in the high-risk level group with an expected half-life of 5.2 y. BMI, body mass index; CMV, cytomegalovirus; eGFR, estimated glomerular filtration rate; KPS, Karnofsky Performance Status; LAS, lung allocation score; TX, transplantation.
in this new era of LTx. We do acknowledge that we were unable to discern between veno-venous (VV) and veno-arterial ECMO use, which may affect posttransplant survival differently and that recent use of ECMO, especially VV-ECMO, to improve transplant candidacy rather than an emergent life-saving therapy, is not factored into the model. However, the advantage of the current statistical strategies is that the different use of ECMO may be accounted for indirectly by analyzing so many variables of the donor/transplant/recipient continuum. Patients placed on VV-ECMO to improve candidacy will be quite different than those placed on emergently or for extracorporeal cardiopulmonary resuscitation.

Findings from previously reported risk prediction models also support the claim of needing to include donor, recipient, and transplant factors into the lung allocation decision-making. The mortality after lung transplantation score showed good predictive strength (C statistic = 0.65) and incorporated both recipient and donor characteristics but only predicted 1-y posttransplant mortality. Another example is the Minnesota-donor-lung quality index, which included 17 recipient- and donor-related risk factors and had a high ability to predict donor utilization (area under the curve = 0.76). However, variable selection in that study was restricted to those 17 risk factors subjectively chosen based on a survey score provided by surgeons, in contrast to the statistical methods employed for variable selection in our study. Another model is by Oto and colleagues that showed poor correlation coefficient for 1-y mortality ($r = 0.23$) even though it correlated with early posttransplant outcomes and was externally validated. In addition, the model used a small sample ($n = 87$) from a single center and employed only 5 donor variables. All 3 models predicted early posttransplant outcomes and did not account for long-term outcomes. Our results indicated modest area under the curves for 1-, 5-, and 10-y mortality for the adjusted total risk score even though the LAPT was developed to account for long-term survival outcome.

Although not proven, this study and others suggest an alternative hypothetical scenario. Potentially reallocating low-risk donors to low-risk candidates or to whatever candidate cohort that would have the largest positive affect (increasing the number of transplants and the number of y alive with a transplant) for the whole community must be studied. The present system focuses on getting to transplant primarily, which clinically is not the goal for the whole community. The goal should be to ensure the best transplant matches that will result in the largest positive

### FIGURE 7

**Example 2:** Thirteen-year-old White male diagnosed with cystic fibrosis, with good organ function (kidney, liver, not on ventilator or extracorporeal mechanical oxygenation [ECMO] support) receiving lungs from a donor who is <50 y, nonsmoker, and no diabetes. Transplant was characterized with prolonged ischemia time (>6h). Patient has 85.4% chance of being in the medium-risk level with an expected half-life of 7.3 y. BMI, body mass index; CMV, cytomegalovirus; eGFR, estimated glomerular filtration rate; KPS, Karnofsky Performance Status; LAS, lung allocation score; TX, transplantation.
affect. Having a very ill patient, which we can objectively predict will have a poor result to transplant, use an ideal donor organ is not necessarily a good outcome if a less ideal donor organ could have been used with no significant predicted effect on their survival. This is especially true if that ideal donor organ could now be used for a recipient in whom the predicted survival would significantly increase in comparison to their survival had they received the less ideal donor organ. Supporting evidence for this approach can be found in liver transplantation wherein it was demonstrated that for a given recipient with several potential donors, predicted graft outcomes did not change with recipient characteristics, yet varied based on donor variables. Similarly, Buescher et al proposes a benefit-based allocation to achieve excellent long-term outcomes and increase total life-years saved per year from liver transplantation. The model in this study helps organize the risk factors and determine those with the highest impact on posttransplant outcomes, therefore, predicting survival in a more advanced way to what has been previously described, using an easy-to-use comprehensive risk scoring tool by means of a validated methodology.

In this study, MLAs were used to impute variables with missing data. The variable selection was done using Cox-Lasso model, which was compared with the random forest Cox approach and Cox regression models with backward elimination and was found to have a better prediction. We speculate that the reason is that the Cox-Lasso method applies shrinkage to the variables that have minimal impact on the model, whereas the random forest Cox machine learning method does not. LASSO regression methods are also known to be tolerant methods for dealing with multicollinearity. This is a novel first step in the LTx field, further MLAs will be used and compared in future iterations of this model.

Using the LAPT, clinicians can predict median survival of patients for any risk score (Figure 2B) as well as belonging to 1 of the 3 different risk groups. The risk group was extensively validated using out-of-sample validation data (Table 3 and Figure 4), allowing further to calculate predicted median survival and 1-, 5-, and 10- year survival chance within same risk group. The advantage of using the risk groups in the validation process is that it allowed enough subjects in each risk group. Validating individual risk scores may not be feasible since for some scores there may not be enough validation samples. The categorization of patients is often useful for the prediction tool to be practical. A tool that provides personalized risk prediction for each patient donor organ match is ideal but presently, enough data do not exist to create it. To approach this ideal tool, median survival time with 95% CI was predicted for each individual score (Figure 2B). It is worth noting, however, that patients can differ greatly, and this gradation cannot be caught with the limited variables available, therefore we consider this study as an important first step toward a more precise and advanced prediction tool.

**Strengths and Limitations**

This study analyzed donor organs that were accepted. Further work is needed to determine if this system has a role in assessing lungs that were declined. The UNOS data set captures many key transplant-related variables, however, it is still limited in collecting some center-level donor information (especially specific bronchoscopy findings) and, therefore, precludes a granular analysis of such data. Also, the tool cannot be externally validated using internationally available registries because it was derived from variables available in UNOS that might not be collected in other countries (eg, LAS). Validating a US-based score in another registry is not uncommon and was done for the kidney donor profile index score for example in a European cohort. Therefore, a more comprehensive score is needed to be available for clinicians worldwide. In addition, even though the tool can predict the risk score of patients, there are patients who fall into the outlier values in the intermediate risk group, which could potentially have a similar outcome to either the low- or the high-risk groups.

To our knowledge, this is the first attempt at matching donor-to-recipient and predicting posttransplant long-term outcomes in LTxs using state-of-the-art statistical and machine learning methods. We studied a nationally representative sample of LTx recipients in the contemporary era. The relatively large sample size allowed for examination of characteristics that are not widely available and thus have been rarely, if ever, used in the analysis of the UNOS database. Imputation of variables was very conservative in this study and was only employed to 1 datapoint per record. Therefore, there was less interference in the data and stronger predictability. Also, this study aimed to find a model that would better predict overall rather than short-term survival alone. This deviates from the current system that predominantly aims at increasing the transplants number. Prediction models should not focus solely on decreasing the number of recipients on the waitlist but optimizing their posttransplant outcomes as well. A system that focuses on increasing the number of years alive with a transplant for the whole community would maximize benefit from a limited donor pool. This may mean at times that the most ill patients getting transplanted first is not done. This is also consistent with the growing literature on the use of mechanical assistance to make patients better transplant candidates (eg, good end-organ function, not mechanically ventilated, paralyzed, etc) and the perils of limping into transplant.

In conclusion, LAPT is a scoring system that incorporates donor-, recipient-, and transplant-related factors and could enable matching that goes beyond the stratification of donor versus recipient characteristics. The tool is practical, easy to interpret, and can be widely used by clinicians, in addition to LAS, for the predictability of short- and long-term survival outcomes. Although this current scoring system is a significant step forward, a more precise model that provides best coupling for each individual recipient and donor organ in real-time rather than in cohorts is a continued focus of our efforts. We hope this tool is an initial step in contributing to a lung allocation system that can maximize utilization of organs and posttransplant outcomes for the overall community.

**ACKNOWLEDGMENTS**

This work was funded by National Institute of Health (NIH 1R01HL147957-01). The data used were obtained from OPTN. Therefore, the work was supported in part...
by Health Resources and Services Administration contract 234-2005-37011C. We would like to acknowledge the support of the Biomedical Informatics team at CCHMC (Ronald Bryson and Jeremy Nix) for developing the webpage. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

REFERENCES

1. Keeshan BC, Rossano JW, Beck N, et al. Lung transplant waitlist mortality: height as a predictor of poor outcomes. Pediatr Transplant. 2015;19:294–300.
2. Israni AK, Zain D, Rosendale JD, et al. OPTN/SRTR 2012 annual data report: deceased organ donation. Am J Transplant. 2014;14 Suppl 1:S167–S183.
3. Eurotransplant International Foundation. Annual Report 2014. Available at http://www.eurotransplant.org/wp-content/uploads/2012/12/eat2014.pdf. Accessed April 21, 2021.
4. Thabet G, Christie JD, Kremers WK, et al. Survival differences following lung transplantation among US transplant centers. JAMA. 2010;304:53–60.
5. Rao PS, Schaubel DE, Guildinger MK, et al. A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index. Transplantation. 2009;88:231–236.
6. Stewart DE, Kucheryavaya AY, Klassen DK, et al. Changes in deceased donor kidney transplantation one year after KAS implementation. Am J Transplant. 2016;16:1834–1847.
7. Hart A, Gustafson SK, Skews MA, et al. OPTN/SRTR 2015 annual data report: early effects of the new kidney allocation system. Am J Transplant. 2017;17 Suppl 1(Suppl 1):S434–S564.
8. Zena TJ, Danobella JS, Levenson G, et al. The impact of kidney donor profile index on delayed graft function and transplant outcomes: a single-center analysis. Clin Transplant. 2018;32:e13190.
9. Seth S, Najjar R, Peng A, et al. Allocation of the highest quality kidneys and transplant outcomes under the new kidney allocation system. Am J Kidney Dis. 2019;73:605–614.
10. Moreno P, Alvarez A, Santos F, et al. Extended recipients but not extended donors are associated with poor outcomes following lung transplantation. Eur J Cardiothorac Surg. 2014;45:1040–1047.
11. Trivedi JR, Cheng A, Ising M, et al. Heart transplant survival based on recipient and donor risk scoring: a UNOS database analysis. ASAIO J. 2016;62:297–301.
12. Woodsdie KJ, Merion RM, Leichtman AB, et al. Utilization of kidney donors with similar kidney donor risk index values from standard versus expanded criteria donors. Am J Transplant. 2012;12:2106–2114.
13. Kwiat SM, Reventlow A, Wilt JS, et al. Outcomes of extended donor lung recipients after lung transplantation. Transplantation. 2005;79:310–316.
14. Pierre AF, Sekine Y, Hutchenson MA, et al. Marginal donor lungs: a reassessment. J Thorac Cardiovasc Surg. 2002;123:421–7; discussion, 427.
15. Lardinois D, Banyash M, Korom S, et al. Extended donor lungs: eleven years experience in a consecutive series. Eur J Cardiothorac Surg. 2005;27:762–767.
16. Beal EW, Tumin D, Coniah LF, et al. Impact of recipient and donor obesity match on the outcomes of liver transplantation: all matches are not perfect. J Transplant. 2016;2016:9709430.
17. Grimm JC, Valero V 3rd, Magruder JT, et al. A novel risk score that incorporates recipient and donor variables to predict 1-year mortality in the current era of lung transplantation. J Heart Lung Transplant. 2015;34:1449–1454.
18. Buuren SV. Flexible Imputation of Missing Data. 2nd ed. Chapman and Hall/CRC; 2018.
19. Dempster A, Laird N, Rubin D. Maximum likelihood from incomplete data via the EM algorithm. J R Stat Soc: Ser B (Methodol). 1977;39:1–22.
20. Spann A, Yasodhara A, Kang J, et al. Applying machine learning in liver disease and transplantation: a comprehensive review. Hepatology. 2020;71:1093–1105.
21. Mark E, Goldisman D, Gurbaxani B, et al. Using machine learning and an ensemble of methods to predict kidney transplant survival. PLoS One. 2019;14:e0200908.
22. Lao L, Kankanihe Y, Rubinstein B, et al. Machine-learning algorithms predict graft failure after liver transplantation. Transplantation. 2017;101:e125–e132.
23. Aylton MD, Ciria R, Cruz Ramirez M, et al. Validation of artificial neural networks as a methodology for donor-recipient matching for liver transplantation. Liver Transpl. 2018;24:192–203.
24. Valapour M, Lehr CJ, Van Arsdalen MA, et al. SRTR 2018 annual data report: Lung. Am J Transplant. 2020;20(Suppl 1):127–508.
25. Demir A, Coosemans W, Decaluwe H, et al. Donor-recipient matching in lung transplantation: which variables are important?†. Eur J Cardiothorac Surg. 2015;47:974–983.
26. Hayes D Jr, Black SM, Tobias JD, et al. Influence of donor and recipient age in lung transplantation. J Heart Lung Transplant. 2015;34:43–49.
27. Hall DJ, Jing El, Gregg JA, et al. The impact of donor and recipient age: older lung transplant recipients do not require younger lungs. Ann Thorac Surg. 2019;107:868–876.
28. Yusen RD, Edwards LB, Dipchand AL, et al; International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: thirty-third adult lung and heart-lung transplant report–2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant. 2017;36:1156–1165.
29. Mabialangan C, Preiksaitis J, Cervera C; University of Alberta Cardiothoracic Transplant Group. Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients. Transpl Int. 2018;31:212–219.
30. Loo R, Radoschewich DM, Kelly RF, et al. The University of Minnesota donor lung quality index: a consensus-based scoring application improves donor lung use. Ann Thorac Surg. 2016;102:1156–1165.
31. Otto T, Lewvey BJ, Whitford H, et al. Feasibility and utility of a lung donor score: correlation with early post-transplant outcomes. Ann Thorac Surg. 2007;83:257–263.
32. Goldberg DS, French B, Abt PL, et al. Superior survival using living donors and donor-recipient matching using a novel living donor risk index. Transplantation. 2016;90:1717–1726.
33. Bueschner N, Seehofer D, Helbig M, et al. Evaluating twenty-years of follow-up after orthotopic liver transplantation, best practice for donor-recipient matching: What can we learn from the past era? World J Transplant. 2016;6:599–607.
34. Chambers DC, Yusen RD, Cherikh WS, et al; International Society for Heart and Lung Transplantation. The registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult lung and heart-lung transplant report–2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant. 2017;36:1047–1059.
35. Sabashnikov A, Weymann A, Mohite PN, et al. Risk factors predictive of one-year mortality after lung transplantation. Eur J Cardiothorac Surg. 2014;46:e82–e88.
36. Zafar F, Jacques BS, Almond CS, et al. Pediatric Heart Donor Assessment Tool (PH-DAT): A novel donor risk scoring system to predict 1-year mortality in pediatric heart transplantation. J Heart Lung Transplant. 2018;37:332–339.
37. Dahmen M, Becker F, Ravenstädten H, et al. Validation of the Kidney Donor Profile Index (KDPI) to assess a deceased donor’s kidneys’ outcome in a European cohort. Sci Rep. 2019;9:11234.